Why is Smith & Nephew stock sliding today?

Smith & Nephew stock fell 1.9% to trade at 1096.5p after the company released its third-quarter trading update, simultaneously cutting its full-year financial outlook and confirming the end of strategic merger discussions with Johnson & Johnson’s orthopaedics arm.

The company reported Q3 revenue of $1.55 billion, up 3.4% year-on-year, but the headline figure was overshadowed by a sweeping revision to annual targets driven by weaker-than-expected demand for hip and knee implants in the United States.

The guidance reductions were substantial across every key metric: full-year underlying revenue growth was trimmed to around 3% from around 4%, trading profit growth was cut to around 4% from around 8%, free cash flow guidance was lowered to approximately $750 million from $800 million, and adjusted return on invested capital was revised down to around 9% from a prior target of above 10%.

Adding to the disappointment, the company confirmed it had approached J&J earlier in 2026 about a potential combination with DePuy Synthes, but those conversations have since ended — eliminating what the market had viewed as a potential transformational catalyst for the struggling Orthopaedics segment.

The broader London market provided little shelter. The FTSE 100 was already under pressure today as investors weighed Democratic gains in U.S. midterm elections, renewed U.S.-Iran geopolitical tensions, and rising crude oil prices that have stoked inflation concerns.

The Bank of England is widely expected to deliver a 25-basis-point rate hike on Thursday, keeping UK equity sentiment cautious and limiting any appetite to buy into weakness in rate-sensitive healthcare names.

The combination of a company-specific guidance shock, the removal of a merger-driven re-rating story, and a risk-averse macro backdrop proved a potent mix for sellers.

With the stock already trading well below its 52-week high of 1426.5p and having touched a 52-week low of 980.4p earlier in the year, investors are now focused on whether management’s pledge to continue exploring strategic options for Orthopaedics can restore confidence in the turnaround narrative.